Current Status of Biomarkers and Molecular Diagnostic Tools for Rejection in Liver Transplantation: Light at the End of the Tunnel?

Ahmed El Sabagh, Islam B. Mohamed, Fuad Z. Aloor, Ahmed Abdelwahab, Manal M. Hassan, Prasun K. Jalal

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Strategies to minimize immune-suppressive medications after liver transplantation are limited by allograft rejection. Biopsy of liver is the current standard of care in diagnosing rejection. However, it adds to physical and economic burden to the patient and has diagnostic limitations. In this review, we aim to highlight the different biomarkers to predict and diagnose acute rejection. We also aim to explore recent advances in molecular diagnostics to improve the diagnostic yield of liver biopsies.

Original languageEnglish (US)
Pages (from-to)139-148
Number of pages10
JournalJournal of Clinical and Experimental Hepatology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2023
Externally publishedYes

Keywords

  • Liver transplantation
  • MMDX
  • biomarker
  • donor-derived cell-free DNA
  • immune-suppression
  • micro-RNA
  • molecular diagnosis
  • nano-string
  • rejection

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Current Status of Biomarkers and Molecular Diagnostic Tools for Rejection in Liver Transplantation: Light at the End of the Tunnel?'. Together they form a unique fingerprint.

Cite this